Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Technology appraisal guidance
Reference number: TA276
Published: 27 March 2013

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: final appraisal determination document

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: final appraisal determination document

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: final appraisal determination document
25 January 2013
(554.85 Kb 41 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 23 January 2013